top of page

Latest News

I love writing guest articles and collaborating
See appearances for Asa's events and podcasts 

Jan 31, 2023

Interview

Steven Hoffman

Hemp and CBD Industry Responds to FDA’s Announcement on CBD

Asa and other industry leaders interviewed

Hemp and CBD Industry Responds to FDA’s Announcement on CBD

Jan 24, 2023

Interview

Jennifer Grebow

Is FDA watching heart health supplements in 2023? 2023 Ingredient trends for food, drinks, dietary supplements, and natural products

Asa and other industry leaders interviewed

Is FDA watching heart health supplements in 2023? 2023 Ingredient trends for food, drinks, dietary supplements, and natural products

Jan 20, 2023

Contributing Author

Let's Talk Hemp

FDA Warning Letters, activity and actions in 2022 and what that means for 2023

Hemp Industry 2023 Opportunities Report

FDA Warning Letters, activity and actions in 2022 and what that means for 2023

Jan 18, 2023

Interview

Palmate, LLC

Why CBD Companies Should Re-Examine Their Marketing Content -- NOW

Why CBD Companies Should Re-Examine Their Marketing Content -- NOW

Jan 17, 2023

Interview

Danielle Masterson

House Oversight chair to FDA: Enough is enough

Asa and other industry leaders interviewed

House Oversight chair to FDA: Enough is enough

Dec 20, 2022

Guest Article

Asa Waldstein

Q4 warning letter roundup with Asa Waldstein

In his quarterly update, consultant Asa Waldstein identifies trends in FDA warning letters impacting manufacturers and marketers of dietary supplements.

Q4 warning letter roundup with Asa Waldstein

Nov 23, 2022

Interview

Judy Blatman

Stay in your lane: Novel delivery systems must comply with supplement regulations

Asa and other industry leaders interviewed

Stay in your lane: Novel delivery systems must comply with supplement regulations

Nov 17, 2022

Guest Article

Asa Waldstein

Beauty-From-Within Marketing: Best Practices and Pitfalls to Avoid

Beauty-From-Within Marketing: Best Practices and Pitfalls to Avoid

Nov 17, 2022

Interview

Danielle Masterson

‘Warning letter geek’ decodes marketing compliance

Asa Waldstein is principal of the Supplement Advisory Group and the man behind 'Warning Letter Wednesdays.' His bread and butter is educating companies about the dos and don'ts of marketing.

‘Warning letter geek’ decodes marketing compliance

Oct 12, 2022

Press Mention

Maggie Jaqua

Regulatory and Enforcement Update on Notable Action in the Cognition, Adaptogen & Nootropic Space

Tune in to hear Asa Waldstein of the Supplement Advisory Group, a boutique group focusing on marketing risk analysis and practical marketing solutions for the web and social media, discuss the latest need-to-know regulatory information impacting the cognition, adaptogen, and nootropic space.

Regulatory and Enforcement Update on Notable Action in the Cognition, Adaptogen & Nootropic Space

Oct 12, 2022

Guest Article

Asa Waldstein

Common Practitioner Pitfalls to Avoid When Marketing Dietary Supplements

Practitioners who sell supplements need to be aware that health and medical claims made in nutritional marketing can attract unwanted attention from the US Food and Drug Administration.

Common Practitioner Pitfalls to Avoid When Marketing Dietary Supplements

Sep 28, 2022

Guest Article

Asa Waldstein

Q3 warning letter roundup with Asa Waldstein

In his quarterly update, consultant Asa Waldstein identifies trends in FDA warning letters impacting manufacturers and marketers of dietary supplements.

Q3 warning letter roundup with Asa Waldstein

Aug 5, 2022

Press Mention

Rachel Adams

Compliance responsibilities when using a contract manufacturer

Brands need to ensure regulatory responsibilities are accounted for at the start of a contract manufacturing partnership.

Compliance responsibilities when using a contract manufacturer

Aug 1, 2022

Interview

Mychealla Rice

The Future of CBD research, marketing, and regulation

In this interview, Professor Ted Dinan, Medical Director at Atlantia Clinical Trials, and Asa Waldstein, Principal at Supplement Advisory Group, discuss Atlantia’s expertise in clinical trials for CBD

The Future of CBD research, marketing, and regulation

Jul 8, 2022

Interview

Sheldon Baker

Limiting Marketing Risk for Hemp and CBD Products

Asa Waldstein, principal at Supplement Advisory Group, advises companies on how to navigate murky waters in today's marketplace.

Limiting Marketing Risk for Hemp and CBD Products

Jun 1, 2022

Press Mention

Josh Long

NDI warning letters fuel criticism of FDA enforcement approach—again

Former FDA officials and lawyers who advise clients on FDA regulations weigh in on a recent batch of warning letters targeting new dietary ingredients marketed in supplements.

NDI warning letters fuel criticism of FDA enforcement approach—again

May 3, 2022

Guest Article

Asa Waldstein

Compliance Essentials for Hemp-CBD Companies, Part 3 of 3: Marketing

Compliance Essentials for Hemp-CBD Companies, Part 3 of 3: Marketing

May 3, 2022

Guest Article

Asa Waldstein

Q2 FDA warning letter roundup with Asa Waldstein

In his quarterly update, consultant Asa Waldstein identifies trends in FDA warning letters impacting manufacturers and marketers of dietary supplements.

Q2 FDA warning letter roundup with Asa Waldstein

May 2, 2022

Press Mention, Data Mention

Isabella Davis

Mental Wellbeing in Today's Digital Age

Presentation

Mental Wellbeing in Today's Digital Age

Apr 19, 2022

Interview

EU’s new THC limits for hemp-based products will ‘level the playing field’ for food producers

Asa and other industry leaders interviewed

EU’s new THC limits for hemp-based products will ‘level the playing field’ for food producers
bottom of page